While artificial intelligence (AI) has infiltrated our search results, impacted customer service with mixed results, and touched our lives in lots of minor ways, its impact hasn’t changed most people’s everyday lives. And while many Read more…
Washington has repeatedly tried to bring down prescription costs for seniors, but each round has faced strong industry resistance and legal challenges. The Trump administration’s Most Favored Nation (MFN) policy for Medicare is the boldest Read more…
Not every stock caught in a market-wide selloff deserves to be there, and Jim Cramer thinks investors are lumping one particular chipmaker in with names it does not really belong next to. His argument arrived Read more…
Nvidia (NVDA) CEO Jensen Huang is challenging the people warning that AI could end humanity, suggesting their alarming predictions may serve another purpose. Speaking with CBS News, Huang rejected the ‘AI apocalypse’ debate and questioned Read more…
Gold is the asset people buy when they have stopped believing in promises. Then most of them hand it to a bank in another country for safekeeping, which is itself a promise. That arrangement is Read more…
Americans have paid about $97 billion more for fuel since the Iran war started in late February, roughly $740 extra per household, according to CNN. President Trump says prices will come down after the midterms. Read more…
Veteran analyst Jim Cramer sees something in Apple’s (AAPL) latest launch that is more than a reason for its customers to buy another replacement phone. After visiting Apple’s Manhattan store, the CNBC host praised the Read more…
Most Americans measure retirement preparedness against six-figure targets, which makes a $100 monthly transfer easy to dismiss before the first transfer is even set up. Vanguard published a chart projecting what monthly contributions grow to Read more…
TheStreet aims to feature only the best products and services. If you buy something via one of our links, we may earn a commission. Why we love this deal Fall is the season for flannels. Read more…
Morgan Stanley met privately with Gilead Sciences (GILD) leadership at its 2026 Global Healthcare Conference this month, and the feedback strengthened the bank’s positive view on the stock. Morgan Stanley’s biopharma team hosted a meeting Read more…